Entity

Time filter

Source Type

Nishi-Tokyo-shi, Japan

Masaki T.,Kyorin University | Sugihara K.,Tokyo Medical and Dental University | Nakajima A.,Yokohama City University | Muto T.,Cancer Institute Hospital Ariake
Surgery Today | Year: 2012

Background: No appropriate management of chronic intestinal pseudo-obstruction (CIP) has been established. Patients and methods: The clinicopathological parameters of 103 cases collected by a nationwide questionnaire study were reviewed. Results: The CIP cases were primary in 86 (83%) cases and secondary in 15 (15%) cases. The age of onset of the primary type was significantly younger than that of the secondary type (p = 0.011). The diseased segments of the bowel were the large bowel in 60 (58%), the small bowel in 17 (17%), and both in 23 (22%) cases, respectively. Abdominal distension and pain were common symptoms regardless of the types of the diseased bowel; however, constipation was frequently seen in the large bowel type (p = 0.0258). Vomiting and diarrhea were seen with marginally higher frequency in the small bowel type (p = 0.0569, 0.0642). Surgical treatment was most effective in the large bowel type, less effective in the small bowel type, and least effective in the large and small bowel type. The prognosis of the primary CIP was significantly better than that of the secondary CIP (p = 0.033). Conclusions: The segments of the diseased bowels should be considered in determining the indications for surgical treatments in CIP patients. © 2012 Springer. Source


Sugiura S.,Nagoya University | Sugiura S.,Medical Device Information Certificate Center | Nakanishi H.,Medical Device Information Certificate Center | Nakanishi H.,Doshisha Womens College of Liberal Arts | And 8 more authors.
Journal of Oncology Pharmacy Practice | Year: 2011

Purpose. A multicenter field survey of environmental contamination and exposure of healthcare professionals to anticancer drugs were performed. Setting. Three university hospitals, one cancer specialty hospital and two corporate hospitals from across Japan. Method. The environmental contamination with cyclophosphamide (CP) was investigated. A wipe examination was performed at six sites apiece in two divisions. The urinary excretion of the CP over 24 h was determined. The subjects of the survey included physicians, pharmacists, and nurses, for a total of seven at each facility irrespective of job title. The wipe samples were collected at 12 sites within two divisions at each facility. For the exposure survey, the total urine volume was determined, and a portion of the urine sample was then collected from each participants at each facility. Urine was collected for 24 h. The samples were determined by using the GC-MS method. Results. Wipe examination: contamination with CP was identified at 50% of the sites. The concentration was high (CP > 1.00 ng/cm 2) in the general environment in two hospitals and in the safety cabinet in one hospital. In the survey for the exposure of staff to anticancer drugs, 276 samples were obtained from 41 healthcare professionals. CP was detected in 90 samples obtained from 23 subjects. The amount of exposure was greatly different among the facilities. The urinary excretion of CP per subject was between 2.7 and 462.8 ng/24 h. The range of urinary excretion for each hospital was between 4.6 and 211.2 ng/24 h. © The Author(s) 2010. Source


Katsumata N.,National Cancer Center Hospital | Hirai Y.,Cancer Institute Hospital Ariake | Kamiura S.,Japan National Cardiovascular Center Research Institute | Sugiyama T.,Iwate Medical University | And 4 more authors.
Annals of Oncology | Year: 2011

Background: S-1 is an oral fluoropyrimidine. This phase II study was designed to evaluate the efficacy and safety of S-1 in patients with advanced or recurrent uterine cervical cancer. Patients and methods: S-1 35 mg/m 2 was given twice daily for 28 days repeated every 6 weeks. Eligible patients were women aged 20-74 years, who had Eastern Cooperative Oncology Group performance status of zero or one, who had stage IVB or recurrent uterine cervical cancer, and who had received no more than one platinum-containing chemotherapy regimen for stage IVB or recurrent disease. The primary end point was overall response rate (ORR) determined by RECIST. Results: A total of 37 patients were enrolled in the trial and 36 were eligible. The median number of cycles administered was 4. The confirmed ORR was 30.6% (95% confidence interval 15.5% to 45.6%). The response rate for patients who had received platinum-based treatment including chemoradiotherapy was 31.8% (7 of 22). After a median follow-up duration of 25 months, the median time to progression and the median survival time were 5.2 and 15.4 months, respectively. The most frequent grade 3 or 4 adverse events were anemia (16%), anorexia (16%), and diarrhea (22%). Conclusions: This phase II study of S-1 in cervical cancer suggests a promising response rate and a contribution toward prolonging survival, with modest toxic effects. Phase III studies of S-1 in patients with advanced or recurrent cervical cancer are thus warranted. © The Author 2011. Published by Oxford University Press on behalf of the European Society for Medical Oncology. Source

Discover hidden collaborations